Breaking News

WuXi PharmaTech Breaks Ground for New Changzhou Campus

May 9, 2014

Will provide early stage preclinical to commercial production

WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., began construction of a new R&D and cGMP manufacturing site in Changzhou, China. 
The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Phase one will double the company's current manufacturing capacity and is expected to be operational by 4Q15. Once the entire project is complete, the site will triple current capacity and employ approximately 1,500 chemists, production staff, and support staff.
"This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016